Diligence memo · auto-generated · as of July 2, 2026
Pharmagen, Inc.
Pharmagen, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Pharmagen, Inc. operates in Pharmaceuticals, based in SILVER SPRING.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pharmagen, Inc. has raised $506K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $400K on 2012-12-12.
Most recent recorded round closed around 2013-06-19.
Valuation (modeled)modeled
Provath models Pharmagen, Inc. at approximately $5.0M (range $59K–$57M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.44× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 13.0 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 13% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.